CONSTANT LEVERAGE LONG - NOVO-NORDISK B | Real-time Euronext Paris 05:53:44 23/05/2024 pm IST | ||
| 0.545 EUR | +20.31% |
|
| Current month | -49.16% | ||
| 1 month | -42.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 23/24/23 | 0.545 | +20.31% |
| 22/24/22 | 0.453 | -5.43% |
| 21/24/21 | 0.479 | +41.72% |
| 17/24/17 | 0.338 | -19.52% |
| 16/24/16 | 0.42 | -7.69% |
Real-time Euronext Paris
Last update May 23, 2024 at 05:53 pm IST
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| 0NJMB | |
| ISIN | NLBNPNL2HOD0 |
| Date issued | 04/09/2023 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.145 € |
|---|---|
| Lowest since issue | 0.08 € |
| Spread | 0.013 € |
| Spread % | 2.27% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
923
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.49%
- Stock Market
- Certificates
- 0NJMB Certificat
